235 related articles for article (PubMed ID: 34068300)
1. Glioblastoma Metabolomics-In Vitro Studies.
Jaroch K; Modrakowska P; Bojko B
Metabolites; 2021 May; 11(5):. PubMed ID: 34068300
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.
Zhao H; Heimberger AB; Lu Z; Wu X; Hodges TR; Song R; Shen J
Oncotarget; 2016 Apr; 7(15):20486-95. PubMed ID: 26967252
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics enables precision medicine: "A White Paper, Community Perspective".
Beger RD; Dunn W; Schmidt MA; Gross SS; Kirwan JA; Cascante M; Brennan L; Wishart DS; Oresic M; Hankemeier T; Broadhurst DI; Lane AN; Suhre K; Kastenmüller G; Sumner SJ; Thiele I; Fiehn O; Kaddurah-Daouk R;
Metabolomics; 2016; 12(10):149. PubMed ID: 27642271
[TBL] [Abstract][Full Text] [Related]
4. Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation.
Katsila T; Matsoukas MT; Patrinos GP; Kardamakis D
OMICS; 2017 Aug; 21(8):429-439. PubMed ID: 28816643
[TBL] [Abstract][Full Text] [Related]
5. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic signature of brain cancer.
Pandey R; Caflisch L; Lodi A; Brenner AJ; Tiziani S
Mol Carcinog; 2017 Nov; 56(11):2355-2371. PubMed ID: 28618012
[TBL] [Abstract][Full Text] [Related]
7. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research.
Ahmed M; Semreen AM; El-Huneidi W; Bustanji Y; Abu-Gharbieh E; Alqudah MAY; Alhusban A; Shara M; Abuhelwa AY; Soares NC; Semreen MH; Alzoubi KH
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613792
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas.
Hirata K; Terasaka S; Shiga T; Hattori N; Magota K; Kobayashi H; Yamaguchi S; Houkin K; Tanaka S; Kuge Y; Tamaki N
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):760-70. PubMed ID: 22307533
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
11. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.
Vogel TW; Zhuang Z; Li J; Okamoto H; Furuta M; Lee YS; Zeng W; Oldfield EH; Vortmeyer AO; Weil RJ
Clin Cancer Res; 2005 May; 11(10):3624-32. PubMed ID: 15897557
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of microRNA expression profile in malignant glioma tissues.
Piwecka M; Rolle K; Belter A; Barciszewska AM; Żywicki M; Michalak M; Nowak S; Naskręt-Barciszewska MZ; Barciszewski J
Mol Oncol; 2015 Aug; 9(7):1324-40. PubMed ID: 25864039
[TBL] [Abstract][Full Text] [Related]
13. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
15. Beyond grade: molecular pathology of malignant gliomas.
Sulman EP; Guerrero M; Aldape K
Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
[TBL] [Abstract][Full Text] [Related]
16. Precision medicine advancements in glioblastoma: A systematic review.
Iyer K; Saini S; Bhadra S; Kulavi S; Bandyopadhyay J
Biomedicine (Taipei); 2023; 13(2):1-13. PubMed ID: 37937301
[TBL] [Abstract][Full Text] [Related]
17. Targeting glioma-initiating cells via the tyrosine metabolic pathway.
Yamashita D; Bernstock JD; Elsayed G; Sadahiro H; Mohyeldin A; Chagoya G; Ilyas A; Mooney J; Estevez-Ordonez D; Yamaguchi S; Flanary VL; Hackney JR; Bhat KP; Kornblum HI; Zamboni N; Kim SH; Chiocca EA; Nakano I
J Neurosurg; 2020 Feb; 134(3):721-732. PubMed ID: 32059178
[TBL] [Abstract][Full Text] [Related]
18. Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity.
Oizel K; Chauvin C; Oliver L; Gratas C; Geraldo F; Jarry U; Scotet E; Rabe M; Alves-Guerra MC; Teusan R; Gautier F; Loussouarn D; Compan V; Martinou JC; Vallette FM; Pecqueur C
Clin Cancer Res; 2017 Oct; 23(20):6292-6304. PubMed ID: 28720668
[No Abstract] [Full Text] [Related]
19. The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations.
Quinones A; Le A
Adv Exp Med Biol; 2021; 1311():59-76. PubMed ID: 34014534
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
